Addressing Disparities in Care and Integrating Antibody‐Drug Conjugates as Treatment for Patients with TNBC
Speakers: Tiffany Traina, MD, Vice Chair, Oncology CareLori Wilson, MD, Associate Dean of Faculty Affairs, COM
Duration: 60 minutes
Presented on: April 22, 2022
Tiffany Traina, MD
Tiffany Traina, MD
Vice Chair, Oncology CareDr. Tiffany A. Traina is an Associate Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. She serves as the Vice Chair, Oncology Care for the Department of Medicine and Section Head of the Triple Negative Breast Cancer Clinical Research Program. She is Co-Chair of the MSK Outpatient Operations Committee and has served as the Clinical Director of the Breast Medicine Service. She is Associate Professor of Medicine at Weill Cornell Medicine in New York City. Her research program centers on the development of therapies for patients with breast cancer, with a particular focus on Triple Negative Breast Cancer and the role of the androgen receptor. Dr. Traina has served on numerous ASCO committees including the Scientific Program Committee for the ASCO Triple Negative Breast Cancer/Cytotoxics/Local Therapy track and she is past Chair for the ASCO Membership Committee 2020-2021 as well as the Co-Chair of the Breast Cancer Guidelines Advisory Group. Dr Traina is a graduate of the 2016-2017 ASCO Leadership Development Program and the MSK Physician Executive Development Program. She is a founding member of the Translational Breast Cancer Research Consortium Triple Negative Breast Cancer Working Group. Her research efforts have led to many publications, peer-reviewed funding, and competitive funding. She has received recognition for her teaching from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine and has been acknowledged with the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation and the Hero Award from the Triple Negative Breast Cancer Foundation.
Lori Wilson, MD
Lori Wilson, MD
Associate Dean of Faculty Affairs, COM
CME InformationAddressing Disparities in Care and Integrating Antibody-Drug Conjugates as Treatment for Patients with Triple-Negative Breast Cancer (TNBC)This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Breast Cancer Foundation, Inc. (NBCF), and Touch, The Black Breast Cancer Alliance (TOUCH).
ACKNOWLEDGEMENTThis activity is supported by an educational grant from Gilead Sciences, Inc.
DATE OF LIVE ACTIVITYFriday, April 22, 2022 from 12:00 – 1:00pm ET
TARGET AUDIENCEThe educational design of this activity addresses the needs of medical oncologists, pathologists, pharmacists, nurse practitioners, physician assistants, nurses, and other HCPs managing patients with TNBC.
STATEMENT OF NEED/PROGRAM OVERVIEWTriple-negative breast cancer (TNBC) is the most aggressive form of breast cancer, disproportionally affecting young Black women. In addition, women from racial minorities tend to be diagnosed at a more advanced stage and experience higher rates of TNBC-related mortality. While standard chemotherapy has a high rate of failure in patients with TNBC, first-in-class targeted therapies offer hope of a more effective treatment for patients.
Join a distinguished panel of expert oncologists to explore how disparities in care negatively affect racial minority patients with TNBC, and the necessary steps healthcare professionals can take to address these inequities. Panelists will discuss how health care professionals can formulate plans to screen and diagnose these patients earlier and include genetic counselors on care teams to support patients after diagnosis. Experts will also review the evolving TNBC treatment landscape, the safety and efficacy of the newly approved anti-TROP-2, and additional agents under investigation.
Can your patients benefit from related education on the recognition and treatment of TNBC? Direct your patients to CancerCoachLive.com to access the patient-education activity, “Facing TNBC: Self-Advocacy and Decision-making.”
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Discuss solutions to address disparities in care for women of ethnic minorities diagnosed with TNBC
- Review recent advances in TNBC pathogenesis and prognosis
- Coordinate referrals to genetic testing and counseling
- Evaluate the mechanisms of action and safety and efficacy data for current and emerging TNBC agents
- Facilitate patient-centered care through accounts of real-world patient experiences
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATIONGlobal Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURE OF CONFLICTS OF INTERESTGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Tiffany A. Traina, MD
Vice Chair, Oncology Care
Triple Negative Breast Cancer Clinical Research Program
Associate Attending Physician
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
Consulting Fee (e.g., Advisory Board): Agendia, AstraZeneca, Athenex, Ayala Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo, Eisai, Ellipses Pharma, Exact Sciences, Foundation Medicine, Fuji Pharma, Genentech/Roche, Gilead Sciences, Ionis, Iteos Therapeutics, Merck, Pfizer, Puma Biotechnology, Seattle Genetics
Contracted Research - Paid to Institution: AstraZeneca, Astellas Pharma, Ayala Pharmaceuticals, Carrick Pharm, Daiichi Sankyo, Eisai, Genentech/Roche, Innocrin Pharma, Immunomedics, Novartis, Pfizer
Lori L. Wilson, MD
Associate Dean of Faculty Affairs, COM
Division Chief, Surgical Oncology
Chief of Breast Oncology
Howard University Hospital and College of Medicine
Nothing to disclose
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Rhys Williams, RN, MSN, FNP Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Jaimee Harris-Gold Nothing to disclose Colleen Heffner Nothing to disclose Tariqa Ackbarali Nothing to disclose Juliet Copeland - Patient Participant Nothing to disclose Nicki Davis - Patient Participant Nothing to disclose Barbara Kaye - Patient Participant Nothing to disclose Yolanda Thomas - Patient Participant Nothing to disclose
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMERParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATIONAccreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.